TRASTUZUMAB (Herceptin) prior authorization at Elevance Health
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
Elevance Health requires HER2/neu Receptor Antagonist prior-authorization documentation for TRASTUZUMAB (Herceptin): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return in 30 days; if denied, prescribers and members have 180 days to appeal.
The PA criteria you'll need to meet
Elevance Health reviews TRASTUZUMAB (Herceptin) prior authorizations against its medical policy for HER2/neu Receptor Antagonist. Elevance Health-specific context: Operates Anthem BCBS in 14 states. Owns Carelon (formerly AIM) which manages utilization for specialty drugs and advanced imaging. State complaint route is to the state insurance department where the policy was issued.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in HER2/neu Receptor Antagonist
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Elevance Health's medical policy URL referenced in the cover letter
Elevance Health's common denial patterns
Pre-empting these patterns in the initial submission cuts rework and shortens time-to-approval:
- Step therapy
- Medical necessity for biologics
- Out-of-network for behavioral health
- Bariatric surgery prior auth
TRASTUZUMAB (Herceptin)-specific denial patterns and context
Across payers (not just Elevance Health), TRASTUZUMAB (Herceptin)draws a distinct set of denial reasons rooted in the drug's label, REMS, and competitive landscape:
- Plan-mandated biosimilar switch mid-treatment
- HER2 IHC 2+ with FISH equivocal — plan demands IHC 3+
- Adjuvant duration beyond 1 year
- Site-of-care reduction
Brand: Herceptin. Reference biologic for HER2-positive breast and gastric cancer. Biosimilars: Kanjinti, Trazimera, Ogivri, Ontruzant, Herzuma. Also a component of Enhertu (trastuzumab deruxtecan, separate molecule) and Kadcyla.
Manufacturer patient-assistance program: Genentech Patient Foundation — relevant when an Elevance Health denial sticks and the patient needs bridge access while appealing.
How Elevance Health approaches Biosimilars PAs
Elevance Health's Biosimilars reviewer typically anchors TRASTUZUMAB (ONTRUZANT) prior-auth decisions on step therapy and medical necessity for biologics. Pharmacy-benefit review for TRASTUZUMAB (ONTRUZANT) at Elevance Health is routed through CarelonRx (utilization management via Carelon, formerly AIM Specialty Health). The 30-day standard review window starts when the prior-authorization request is received with all required documentation — incomplete packets pause the clock and add 5-10 days to time-to-approval, after which the 180-day internal-appeal window begins from the denial date. Elevance Health treats interchangeability designation and prescriber "dispense-as-written" language as the two pivot points for biosimilar-vs-reference disputes. Elevance Health is domiciled in IN, so unresolved appeals escalate to the IN insurance department's external-review program for fully-insured policies (self-funded ERISA plans route to the DOL EBSA instead). Operates Anthem BCBS in 14 states.
If the PA is denied
Elevance Health gives prescribers and members 180 days to file an internal appeal. Standard appeal decisions return within 30 days. Submit through the provider portal (https://providers.anthem.com) with the same packet plus a peer-reviewed citation supporting TRASTUZUMAB (Herceptin)for the patient's indication.
Contact Elevance Health
- Provider portal: https://providers.anthem.com
Frequently asked questions
What documentation does Elevance Health need for TRASTUZUMAB (Herceptin) prior auth?
Elevance Health's typical PA packet for TRASTUZUMAB (Herceptin): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis. For HER2/neu Receptor Antagonist, expect clinical-criteria documentation specific to this class.
What's the turnaround time at Elevance Health?
Standard TRASTUZUMAB (Herceptin) PA decisions at Elevance Health: 30 days. Urgent / expedited (member's life or function at risk): 72 hours under 45 CFR §147.136.
What does Elevance Health most often reject TRASTUZUMAB (Herceptin) for?
Across Elevance Health's book the common rejection patterns include: Step therapy; Medical necessity for biologics; Out-of-network for behavioral health. For TRASTUZUMAB (Herceptin) specifically, expect step-therapy challenges and indication-restriction reviews when the use is at the edge of the FDA label or off-label.
Can Elevance Health force a mid-treatment switch from the reference biologic to TRASTUZUMAB (ONTRUZANT)?
Elevance Health can require biosimilar use at initiation, but mid-treatment forced switches face higher appeal-reversal rates when the chart documents a stable patient, a defined transition-of-care concern, or prescriber "dispense-as-written" intent supported by a clinical rationale (immunogenicity history, nocebo response in prior switches, narrow therapeutic window). Cite the FDA Purple Book interchangeability designation when arguing the switch — interchangeable biosimilars permit pharmacy substitution; non-interchangeable biosimilars do not. Pharmacy-benefit handling is routed through CarelonRx (utilization management via Carelon, formerly AIM Specialty Health). External-review escalation for Elevance Health fully-insured policies sits with the IN insurance department.
How do I prep for a peer-to-peer with Elevance Health on TRASTUZUMAB (Herceptin)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the TRASTUZUMAB (Herceptin) PA packet
Open ApprovalHelp — generate a TRASTUZUMAB (Herceptin) prior-auth packet tailored to Elevance Health's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com